Mobocertinib Use in Platinum-Pretreated Patients With EGFR Exon 20 Insertion–Positive mNSCLC

Expert oncologists review data from the EXCLAIM cohort, which analyzed mobocertinib use in platinum-pretreated patients with EGFR exon 20 insertion–positive mNSCLC.

Shared insight on efficacy data with mobocertinib from the EXCLAIM cohort of patients with platinum-pretreated EGFR exon 20 insertion–positive mNSCLC.

Focused discussion on the safety profile of mobocertinib in platinum-pretreated EGFR exon 20 insertion–positive mNSCLC given data from the EXCLAIM cohort.

In the context of mobocertinib clinical data, experts consider factors that help them select therapy and manage therapy for patients with EGFR exon 20 insertion–positive mNSCLC.

A brief review of biomarker testing in metastatic non–small cell lung cancer to identify alterations such as the EGFR exon 20 insertion.

Closing out their discussion on mobocertinib data and the EXCLAIM cohort, experts share hope for the future management of the EGFR exon 20 insertion–positive mNSCLC.

Expert oncologists review safety/efficacy data behind mobocertinib, a small molecule tyrosine kinase inhibitor, in patients with EGFR exon 20 insertion–positive metastatic non–small cell lung cancer.